Michael J. Rogers

Nitrogen-Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including Ras

Steven P. Luckman, D. E. Hughes, Fraser P. Coxon et al. · Journal of Bone and Mineral Research · 1998 · 1.2K citations · Full text

Sclerostin, Mevastatin-induced Apoptosis, Molecular Regulation +25

Structure-Activity Relationships for Inhibition of Farnesyl Diphosphate Synthase in Vitro and Inhibition of Bone Resorption in Vivo by Nitrogen-Containing Bisphosphonates

James E. Dunford, Keith Thompson, Fraser P. Coxon et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 893 citations

Cellular and molecular mechanisms of action of bisphosphonates

Michael J. Rogers, Sharon Gordon, Helena L. Benford et al. · Cancer · 2000 · 709 citations

Molecular Physiology, Signal Transduction, Biochemistry +10

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation <i>in vitro</i>

John Fisher, Michael J. Rogers, J. M. Halasy et al. · Proceedings of the National Academy of Sciences · 1999 · 679 citations

Sclerostin, Bone Resorption, Macrophage Apoptosis +17

The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs

K.L. Kavanagh, Kunde Guo, James E. Dunford et al. · Proceedings of the National Academy of Sciences · 2006 · 529 citations · Full text

Enzyme Kinetics, Medicinal Chemistry, Sclerostin +14